CDC: Proportion of Extensively Drug-Resistant Shigella Isolates Increasing

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

TUESDAY, April 14, 2026 -- The proportion of extensively drug-resistant (XDR) Shigella isolates in the United States increased from 2011-2015 to 2023, according to research published in the April 9 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Naeemah Logan, M.D., from the National Center for Emerging and Zoonotic Infectious Diseases at the CDC in Atlanta, and colleagues describe trends and epidemiologic characteristics of XDR shigellosis by analyzing Shigella isolates submitted to the CDC molecular surveillance network for enteric pathogens during Jan. 1, 2011, to Oct. 20, 2023.

The researchers found that 510 (3.0 percent) of the 16,788 isolates with resistance data during the study period were XDR. There was an increase in the percentage of XDR isolates from 0 percent during 2011 to 2015 to 8.5 percent in 2023. Species information was available for 505 of the 510 XDR isolates; of these, 65.9 and 34.1 percent were Shigella sonnei and Shigella flexneri, respectively. The median patient age was 41 years among those with XDR shigellosis, and 86.2 percent of patients were men. Overall, 76.2 percent of those with available travel history reported no recent domestic travel and 82.4 percent reported no recent international travel. A total of 54 of the 116 persons with available HIV status (46.6 percent) reported HIV co-infection.

"Because no oral antimicrobial agents are FDA-approved, prevention, early detection, antimicrobial susceptibility testing-guided therapy, and timely reporting are important to protect populations at higher risk for XDR Shigella infection," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-15 02:08

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords